Please login to the form below

Not currently logged in

Sigma-Tau Pharmaceuticals appoints CEO

Interim CEO Michael Minarich takes up the post in a permanent capacity

Sigma-Tau Pharmaceuticals Michael MinarichRare disease specialist Sigma-Tau Pharmaceuticals has appointed Michael Minarich as chief executive officer.

Micharich has served as the company's interim chief executive since July last year, bringing over 30 years of marketing and business development experience in the pharmaceutical industry to the role.

Prior to joining Sigma-Tau, Micharich was the Pharmacia Corporation's market company president in the Czech Republic and oversaw the merger of Searle with Pharmacia and Upjohn.

He has considerable experience in growing startup businesses and integrating over-the-counter and consumer product mergers and acquisitions, having spent 20 years doing so across Asia, Canada and Europe.

Marco Brughera, chief executive and global head of rare disease at Sigma-Tau Rare Disease, said: “Mr Minarich has demonstrated outstanding leadership over the past year, and his appointment comes at a time of development in the company, as it expands through registration, life-cycle management and commercialisation of its proprietary research and development pipeline.

“The appointment of the chief executive role reflects the commitment Sigma-Tau has to the field of rare diseases, and to the significant impact we expect these medicines will ultimately have on their respective physician and patient communities.”

9th August 2016

From: Sales



Featured jobs

Subscribe to our email news alerts


Add my company
Atlantis Healthcare

Atlantis Healthcare is a global leader in optimising patient self-management. Established in 1996, we design, develop and implement scalable solutions...

Latest intelligence

How to get rep buy-in for multi-channel
How do you manage a team who may be resistant to change?...
Blog: Digital therapeutics: within our reach?
Digital therapeutics is a hot topic right now. By using digital technology to manage, treat or even prevent chronic conditions, digital therapeutics is promising to revolutionise healthcare. But is this...
figure 1
The valuable brand
Creating value beyond the pill is both possible and increasingly necessary...